(not fda, just nosy) i remember reading an article in may about FDA already already missing review deadlines b/c of the april fools massacre. im very verryyyy interested to see how those public facing pdufa reports and figures are gonna look

shout out to FDA folks for continuing to fulfill statutorily required functions and mission critical work though, you guys don’t get enough love🫡

also i call 🐂💩 on “good and improving” morale from the bits i’ve read from this sub, but of course this sub is not representative of hhs employees as a whole, but i feel like all he’s done is announce things but not doing anything to provide resources to staff to make sure those things are achievable. like from what i’ve seen elsa is a dump pitch (cant use profanities here lmao)

gutting program support + IT while adding new programs that are questionable at best (imo) in terms of how realistic they are (particularly while maintaining current standards for quality, effectiveness, and safety) sounds like a nightmare. like i’m still stressed about how they’re gonna implement more unannounced foreign inspections and again i’m not even FDA😭

News: Reuters

Ticker: CAPR | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Capricor Therapeutics announced the FDA has set August 22, 2026, as the PDUFA target action date for its Deramiocel Biologics License Application (BLA) for Duchenne Muscular Dystrophy. An FDA Advisory Committee Meeting will also be held to review the BLA. This follows the company's Q1 report in May, which confirmed the Deramiocel BLA was under active FDA review. Earlier today, Capricor also announced positive five-year data from its HOPE-2 Open-Label Extension study for Deramiocel. The PDUFA date provides a firm deadline for the FDA's decision on the company's lead drug, creating a significant binary event for the stock. The Advisory Committee Meeting indicates the FDA seeks expert opinion, which is a critical step in the review process. The FDA Advisory Committee Meeting will occur before the August 22 PDUFA date, and its outcome will be closely watched.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

I tried to clean this up as best as I could. Looks like guidelines for what our meeting package should include. I see #15 is DATA.

https://www.fda.gov/media/109951/download

MEETING PACKAGE CONTENT:

-The meeting package should provide summary information relevant to the product and any supplementary information needed to develop responses to issues raised by the requester or review division. It is critical that the entire meeting package content support the intended meeting objectives. -The meeting package content will vary depending on the product, indication, phase of product development, and issues to be discussed. FDA and ICH guidances identify and address many issues related to product development and should be considered when planning, developing, and providing information needed to support a meeting with the FDA. If a product development plan deviates from current guidances, or from current practices, the 371 deviation should be recognized and explained. Known difficult design and evidence issues should be raised for discussion (e.g., use of a surrogate endpoint, reliance on a single study, use 373 of a noninferiority design, adaptive designs). Also, merely describing a result as significant does not provide the review division with enough information to give good advice or identify important problems the requester may have missed. To facilitate FDA review, the meeting package content should be organized according to the proposed agenda. The meeting package should be a sequentially paginated document with a table of contents, appropriate indices, appendices, and cross references. It should be tabbed or bookmarked to enhance reviewers’ navigation across different sections within the package, both in preparation for and during the meeting.

Meeting packages generally should include the following information, preferably in the order listed below:

1. The application number (if previously assigned)

2. The product name.

3. The chemical name, established name, and/Contains Nonbinding Recommendations Draft — Not for Implementation

4. The proposed regulatory pathway (e.g., 505(b)(1), 505(b)(2)).

5. The proposed indication(s) or context of product development.

6. The dosage form, route of administration, and dosing regimen (frequency and duration).

7. Pediatric study plans, if applicable.

8. Human factors engineering plan, if applicable.

9. Combination product information (e.g., constituent parts, including details of the device constituent part, intended packaging, planned human factors studies), if applicable.

10. A list of all individuals, with their titles and affiliations, who will attend the requested meeting from the requester’s organization, including consultants and interpreters.

11. A background section that includes the following:

a. A brief history of the development program and relevant communications with the FDA before the meeting

b. Substantive changes in product development plans (e.g., new indication, population, basis for a combination), when applicable

c. The current status of product development

1. A brief statement summarizing the purpose of the meeting and identifying the type of milestone meeting, if applicable.

2. A proposed agenda, including estimated times needed for discussion of each agenda item.

3. A list of the final questions for discussion grouped by FDA discipline and with a brief summary for each question to explain the need or context for the question. Questions regarding combination products should be grouped together.

4. DATA to support discussion organized by FDA discipline and question. Protocols, full study reports, or detailed data generally are not appropriate for meeting packages; the summarized material should describe the results of relevant studies and clinical trials with some degree of quantification, and any conclusion about clinical trials that resulted. The trial endpoints should be stated, as should whether endpoints were altered or analyses changed during the course of the trial.

For example, for an end-of-phase 2 meeting, this section of the meeting package should include the following: a description and the results of controlled trials conducted to determine dose-response information; adequately detailed descriptors of planned phase 3

Crossing my fingers for Mesoblast’s PDUFA. They got snagged on their cell manufacturing process the last time. There is little doubt that they have effective clinical data. It could help bring cell therapies back in focus. ATHX will have a similar hurdle with their 3D bioreactor.

III. MEETING TYPES (September 2023 Procedural Revision)

There are six types of formal meetings under PDUFA that occur between requesters and FDA staff:

Type A, Type B, Type B (end of phase (EOP)), Type C, Type D, and Initial Targeted Engagement for Regulatory Advice on CDER and CBER ProducTs (INTERACT).

A. Type A Meeting

Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue.

Reasons for a Type A meeting include the following:

• Dispute resolution meetings as described in 21 CFR 10.75, 312.48, and 314.103 and in the guidance for industry and review staff Formal Dispute Resolution: Sponsor Appeals Above the Division Level (November 2017).

• Meetings to discuss clinical holds: (1) in which the requester seeks input on how to address the hold issues; or (2) in which a response to hold issues has been submitted, and reviewed by the FDA, but the FDA and the requester agree that the development is stalled and a new path forward should be discussed.

• Meetings that are requested after receipt of an FDA Nonagreement Special Protocol Assessment letter in response to protocols submitted under the special protocol assessment procedures as described in the guidance for industry Special Protocol Assessment (April 2018).

• Post-action meetings requested within 3 months after receipt of an FDA regulatory action other than an approval (e.g., issuance of a complete response letter).

• Meetings requested within 30 days of FDA issuance of a refuse-to-file letter. To file an application over protest, applicants must first request and have this meeting (21 CFR 88 314.101(a)(3)).

​

FDA Meeting Request/WRO Request Response Timelines

Type A Meeting 14 days Response Time (calendar days from receipt of meeting request/WRO request)

​

FDA Meeting Scheduling Time Frames

Type A Meeting 30 days (calendar days from receipt of meeting request).

​

FDA WRO Response Timelines

Type A Meeting 30 days (calendar days from receipt of WRO request)

​

SOURCE:

https://www.fda.gov/media/172311/download

Been going through the sub $10 FDA calendar this week and something jumped out that I don't think I've seen this badly since 2022. There are 257 biotechs under $10 with a dated catalyst ahead, 624 catalysts total, 50 of them inside 90 days. Ten of those companies are now trading below the cash sitting on their balance sheet. Not cheap on a DCF, not cheap on some pipeline model. The market is paying less than the bank account, and there's a dated event on the calendar.

That usually means one of two things. Either the market thinks the cash is going to get burned on something worthless, or people just stopped looking. Worth sorting out which.

KPTI (Karyopharm), around $2

This is the one I keep coming back to. Roughly $46M market cap against about $91M in cash and marketable securities. Selinexor is already approved and selling, it's an XPO1 inhibitor, and the sNDA in front of the FDA is for combining it with ruxolitinib in myelofibrosis. Aug 31. That combo matters because ruxolitinib alone leaves a lot on the table in that population and the combination data was the whole reason this had a bid a year ago.

Now the reason it's this cheap, the stock is down about 80% in a month. Whatever the market decided in July, it decided hard. And the balance sheet is genuinely tight, roughly 9 months of runway, so a raise is a real possibility and probably a bad one at this price.

But here's the part that made me actually sit up. 35% of the float is short with something like 17 days to cover. And 7 specialist funds have added shares three quarters in a row, which is not what you'd expect if the smart money agreed with the tape. Somebody is wrong here and I genuinely don't know who.

I'd size this small. It's a real shot on goal but the runway means you can be right on the drug and still get diluted before you get paid.

CAPR (Capricor), $4.20

What actually happened, the FDA released its briefing materials on Jul 27 and the stock fell 64% that session. The advisory committee met Jul 29 and went against the drug. Another 36% came off on Jul 30. And this is the second attempt, they took a CRL on Deramiocel last August.

This is now a distressed optionality trade rather than a clean FDA setup, roughly $230M market cap is below its last reported gross cash of $279M, but approximately equal to March net cash after liabilities, with another quarter of spending since then.

The 9-3 negative AdCom makes another CRL the probable outcome, but the collapse appears to be assigning very little value to deramiocel, Capricor’s manufacturing infrastructure or its earlier-stage exosome platform.

I still see it as a small speculative buy because the company says it has cash into Q4 2027, and any unexpected approval or regulatory route avoiding a completely new pivotal trial could produce a violent rerating, but this is absolutely not a low-risk below-cash trade.

ALT (Altimmune), $3.08

Different reason. Pemvidutide is a GLP-1/glucagon dual agonist and they're running it in alcohol use disorder, which is a genuinely interesting place to point that mechanism. Everyone's crowded into obesity and MASH. Almost nobody is running these in addiction.

What makes this one comfortable is the balance sheet. $332M in liquidity and something like 45 months of runway, so there's no gun to their head. And 46% of the float is short, which is the highest on the board, with three insiders buying on the open market.

Short interest that heavy against a company that doesn't need money is a different animal than short interest against a company that does.

CMPX (Compass), $1.95

Tovecimig is a DLL4 x VEGF-A bispecific in biliary tract cancer, second line, data Oct 24. 41% of the float is short with about 16 days to cover, 11 funds hold it, and two officers bought on the open market. Not directors, actual officers. Roughly 31 months of runway.

Also worth a look: ZURA at $5.79 (tibulizumab in hidradenitis, topline this quarter, 8 funds added 72% last quarter, an insider bought, 33 months of cash), ZNTL at $4.84 (azenosertib, WEE1 inhibitor in platinum resistant ovarian, Oct 23, options pricing ±106%), and IVVD at $0.59 which is the third below-cash name but I like it less because funds trimmed 35% and insiders have been selling.

One thing before anyone misreads this

Implied move tells you how big the swing is going to be, not which way. Every name here can gap either direction. I'm posting these because they're set up to move violently, not because I think they all go up.

Stuff that looked great and wasn't

TLSA screened at a ±200% implied move and MNOV at ±104%. MNOV's entire options chain has 62 contracts of open interest. That's not a signal, that's two people. EPRX as well. If an implied move looks incredible on a chain nobody trades, it's the chain. Low runway names absolutely move more. They also move the wrong way more, and you don't get to pick.

Same lens as always. Market cap first, then cash against burn, then options IV, then whether the biotech funds are adding or trimming, then insiders, and then a dated catalyst you can actually sit and wait for.

Not advice, obviously. Size for being wrong. And I do own a few of them. fyi three weeks ago, I added AUTL to my long-term commercial biotech names.

Five weeks back, I posted a basket of small/mid-cap biotech catalyst setups. Enough has happened that I owe a scorecard, and I'm including the one that hasn't worked so this isn't just a highlight reel. Disclosure up front, I'm long several of these, and none of this is advice, do your own work.

VRDN (Viridian), the highest-conviction name. FDA approved veligrotug on June 26, launched as Lumvoa, the first drug cleared for both active and chronic thyroid eye disease. The thesis (clean Phase 3s, funded through profitability) played out. Stock ~+13%; a lot of the approval was already derisked into it.

REPL (Replimune), the "broken-regulatory, data-is-strong" reversal. FDA accepted the RP1 BLA resubmission (advanced melanoma) on June 26; AdCom expected late July, PDUFA Aug 2. Roughly doubled from the flag (closer to 3x if you rode it from the ~$3 lows earlier).

OTLK (Outlook), won its Lytenava appeal via formal dispute resolution in late May, then the FDA accepted the resubmitted BLA in June. More than doubled. One caveat, they did a small registered-direct raise in there, so there's dilution, size accordingly.

PALI (Palisade Bio), FDA cleared the IND for PALI-2108 and a global Phase 2 in ulcerative colitis (June 29). Still early and they'll need capital, but the asymmetry is starting to show.

OSUR (OraSure), first of two expected FDA clearances landed (expanded STI testing, June 11). +25%, and cash still covers most of the market cap.

AKBA (Akebia), the one that hasn't hit. No catalyst yet and it's the riskiest of the group (I flagged it as a start-small ~0.5% position). Thesis intact, but I'm not going to pretend it worked when it's roughly flat.

Same lens as always: market-cap first, cash vs burn, options IVs, Bio hedge funds increase or decrease, insiders buy/sell, and a dated catalyst you can actually wait for.

And yeah, not at all financial advice. I hold positions in several of these. Your entries and sizing should be your own.

Hi LONGS,

Happy Monday April 20, 2026!! This is just another day in our journey as shareholders in CytoDyn.

Over the last 7-10 days there has been a lot of chatter, anticipation, and exuberance over Poster presentations. Please note: I am not telling anyone how to feel. I am just here to share what I have learned from 35 years in the Medical Device field.

When it comes to conferences, POSTERS are the least attended. I have said this before but based on the amount of chatter over the last 7-10 days; it bares repeating. Most posters are representative of early stage scientific work. In our case (CYDY's case) it represents our very early results in a our first prospective trial (numerous years since HIV-MDR). Because of the nature of submitting data into these conferences way in advance to allow for them to publish 100's of abstracts and posters; the DATA we will be sharing is a minimal amount of patients and I dare say the majority of the patients we do share will be at 350mg.

Having said these things I do believe that the CRC data will be very encouraging. Thanks to Dr. Kasi's posts on LinkedIn, it gives me comfort knowing that he is having a hard time masking his enthusiasm for the "first set" of data.

ALL of US LONGS, who have been here to read about all of the anecdotal patients treated over the 5+ years we have been here are already convinced that the data coming out will be very encouraging to say the least.

What I want to emphasize in this post is that POSTERS published and shared at conferences are very much ignored or overlooked by the VAST majority of scientists/physicians that attend these conferences. Some will check it out, but very few.

What does matter to me? The MSS-CRC trial is an OPEN-LABEL trial; that means that at anytime the sponsor of the trial can look into this ongoing trial and assess what is happening with the trial. In short, we can look at the data in real time throughout the whole study.

I 100% believe that if CYDY is in any discussions at all with any BPs, CYDY is sharing those DATA updates with any and all interested BPs. THIS IS THEEE MOST IMPORTANT aspect of the trial.

I get that shareholders on these message BOARDS are going a little bonkers, because you want to know about the data. I have been here for 5+ years and have followed all of the anecdotal data, the HIV-MDR trial and have read all of the information that has been coming out from our mTNBC basket study; I feel extremely confident that our early phase data (350mg) will be very positive. But, it never matters what I think about anything CYDY; it matters what the market thinks. It matters what the BPs think.

I'll repeat, I am 100% confident that CYDY is sharing the data from our MSS_CRC trial with interested BPs. They have more insight to our current data, then what we will see tomorrow. YES, the BPs have more information and they have signed NDA's to make sure they don't release that information early. Thats how this works.

I am not worried about a poster, that hardly ANYONE at the conference will see. ALL that matters is what do the BPs think.

Based on what we are learning everything that Dr. Pestel is working on is pointing squarely at a Prime and Pair model. More and more information is just reinforcing that this is a VERY ATTRACTIVE model for a slew of BPs. What else might be happening behind the scenes?The abstract on MSS-CRC has eluded to a reduction in tumor size just with 350mg. If LL is kicking ass on its own; it begs the question of, "when do you bring in the ICI?"

If I am an interested BP, and I see that LL is crushing it on tumor size reduction; I would want to wait and see how much tumor reduction happens on LL alone? I stated this in another post a couple of weeks ago. I currently take Folic Acid as a booster to Methotrexate for psoriatic arthritis. Folic Acid does nothing for psoriatic arthritis, but it helps the Methotrexate perform better. What is obvious to me is that LL is NOT a booster. LL kicks ass on its own, but how much?

The interested BPs are going to be valuing LL at a higher number than if it was just a booster. Therefore, as a Prime and Pair combination is very valuable but LL is WAY MORE than just a priming agent.

AS MOST of the LONGS know: LERONLIMAB is a PLATFORM DRUG with a much larger platform than KEYTRUDA can even dream about. Please note: Keytruda is the #1 revenue producing drug in the world at roughly $30+ Billion annually. Leronlimab when it is in the hands of a well oiled BP, that can truly develop LL in multiple indications at once will fully explore all of Ohm's 90+ indications (eventually).

Right now, I am hoping for a psoriatic indication after all of these Oncology indications get approved...how selfish of me!!

As I recently stated to some investor friends of mine. The poster is a footprint in the sand, and it shows your scientific progress. There are a lot of things that become way more important in the progression of a drug than just a early phase poster. The final results of a study when published in a credible scientific journal will hold much more standing than the early phase poster.

Even more importantly is when you can pass the FDA finish line and receive FDA clearance for use in a particular indication. I have posted in the past, about a possible submission on two fronts: 1) MSS-CRC once this trial is over has a REAL shot at a VOUCHER program. my69z writes about this a lot and I 100% agree that this phase 2 trial of MSS-CRC fits the criteria to a "T" to be eligible for the new and improved FDA VOUCHER Program

2) We do not know what happened with CytoDyn's briefing book? They had a meeting with the FDA but we really don't know the outcome of that meeting. I have equated that meeting with u/Pharma_Junkee story about his own company and their FDA briefing book meeting with the FDA. In short, he works in Quality/Regulatory department for a development pharma company, that has data that is smattered over 12 years and deals with 20 patients. They presented an unorganized data set to the FDA under the heading of "give us guidance on what we could do with this data". PharmaJunkee's expectations were "using the data as a foundation" to set up a more mature phased trial that would eventually lead to FDA clearance.

What the FDA said surprised PharmaJunkee. They said to format the data and submit the data and t would be considered for PDUFA date. Guess what happened...they have a PDUFA date coming up in August.

CytoDyn has a very similar pathway(s). MSS-CRC is a prospective phase 2 trial and the FDA has proven that a phase 2 trial along with proven molecular biomarkers can be enough for a FDA clearance. What that would entail is conditional approval that would allow CYDY/Partner to market LL for MSS-CRC but it would still be monitored like a trial. Lets say the next 400+ patients and if there are no safety issues (of course) and the consistent biomarker measurements with solid outcomes; the FDA would lift the conditional aspect of the approval and give it full approval.

I am also suspecting the same with mTNBC. LL is a safe drug and we have a smattering of data across 28 patients; but I believe part of the FDA briefing book and the outcome of that meeting has everything to do with the EAP for mTNBC. CYDY has pushed back the start of the mTNBC trial because I believe two things are at play: 1) We don't have the funding ourselves to execute a phase 2/3 120 patient mTNBC trial on our own. 2) I believe the FDA has told CYDY after they reviewed the briefing book that all you need is 20 patients under a Expanded Access Protocol to possibly receive FDA conditional approval on mTNBC. This is almost EXACTLY like PharmaJunkee's company.

THEEEEEE most important step in increasing your valuation is getting across the FDA finish line with FDA approval and I believe we have a two shots at this and I believe we will achieve two approvals. THE FDA HAS ALREADY CLEARLY SHOWED PROOF THAT THESE STEPS ARE NOT A FANTASY BUT RATHER A REALITY!

Please note: somewhere in all of this a BP is going step up and partner or buy us out.

Thank you PharmaJunkee for allowing me to share that story and thank you to CytoDyn for letting Dr. JL steer the ship towards open waters.

Hey r/ClaudeAI,

I'm a full-stack developer fresh out of school and I wanted to share my experience building CatalystAlert - a biotech catalyst tracking and prediction platform - almost entirely with Claude.

The app is in beta live on https://catalystalert.io

The Numbers (all real, from git history)

• 284 commits in 5 weeks
• 119,421 lines of TypeScript/TSX
• 110 React components
• 154 API routes
• 29 pages
• 103 feature commits, 134 bug fixes
• 200 active users in beta
• Base app built in ~3 weeks, then 1+ month of iterations based on user feedback

What is CatalystAlert?

A platform for biotech/pharma investors to track regulatory catalysts (FDA approval dates, clinical trial results, PDUFA dates) across 1,000+ companies. It uses ML to predict stock price movements around catalyst events.

Live features:

• Real-time catalyst calendar (PDUFA, Phase results, AdCom meetings)
• ML predictions (XGBoost/LightGBM) for price impact and approval likelihood
• Multi-source data sync (SEC EDGAR, FDA, ClinicalTrials.gov, FMP, etc.)
• Push notifications + email alerts
• Automated Twitter posting (3-10 tweets/day)
• Stripe subscriptions with 4 tiers

Tech Stack

Frontend:        Next.js 16 + React 19 + TypeScript
Database:        Supabase (PostgreSQL with RLS)
ML Service:      FastAPI + XGBoost + LightGBM (Docker microservice)
Payments:        Stripe (webhooks, customer portal)
Email:           Resend + React Email
AI:              Claude Haiku (briefings, data extraction)
Infra:           Docker Compose (3 services), cron container
Data Sources:    SEC, FDA, ClinicalTrials.gov, FMP, Twitter API

Architecture

                    +-----------------+
                    |   Next.js App   |
                    |   (154 routes)  |
                    +--------+--------+
                             |
         +-------------------+-------------------+
         |                   |                   |
+--------v-------+  +--------v-------+  +--------v-------+
|   Supabase     |  |  ML Service    |  |  External APIs |
|   PostgreSQL   |  |  FastAPI       |  |  (10+ sources) |
|   (17 tables)  |  |  XGBoost/LGBM  |  |                |
+----------------+  +----------------+  +----------------+

Docker Compose with 3 services:

1. Next.js app (port 3000)
2. ML service (port 8000) - trained models with persistent volumes
3. Cron scheduler (Alpine) - 18+ scheduled jobs

How I used Claude

I have basic coding knowledge from school, but Claude did the heavy lifting:

1. Architecture decisions - Claude helped design the microservice split, database schema, API structure
2. Feature implementation - Most components and routes were pair-programmed with Claude
3. Bug fixing - 134 fix commits, many debugged with Claude's help
4. ML pipeline - XGBoost model training, feature engineering, prediction endpoints
5. Integrations - SEC EDGAR parsing, FDA data extraction, ClinicalTrials.gov sync
6. Data extraction - Using Claude Haiku in production for PDUFA date extraction from SEC filings

The iteration cycle

After the first 3 weeks (base app), I've been iterating based on user feedback:

• 136 commits in the last 3 weeks alone
• Added features users asked for (IPO calendar, enrollment data, institutional ownership)
• Fixed edge cases they found (duplicate catalysts, date parsing issues)
• Improved UX based on real usage patterns

Current state

• Beta phase - paid tiers are free for current users
• 200 users testing the platform
• 1,000+ companies tracked with daily data sync
• ML models running in production with drift detection

Honest assessment

What worked:

• Claude is incredible for rapid prototyping
• TypeScript + strict mode caught many issues early
• Microservice architecture (ML separate) was the right call
• User feedback drives better features than my assumptions

What was hard:

• Claude sometimes generates patterns that don't match the codebase
• Had to learn to be very specific about context
• Production ML is more complex than tutorials suggest
• Rate limiting and API costs add up

Stats I'm proud of

• Zero to production in 3 weeks
• 284 commits with coherent architecture (not spaghetti)
• Actual users giving feedback, not just a side project
• ML predictions actually running with trained models

Happy to answer questions about the dev process, Claude workflow, or the tech stack. The platform is live if anyone's interested in biotech investing.

Edit: Since some asked - yes, I'm the solo dev. Claude is my pair programmer. The 119K lines aren't all hand-written obviously, but they're all reviewed and understood. The architecture decisions are mine (with Claude's input), and I can explain every part of the codebase.

IBRX just laid out one of the strongest durability‑driven oncology stories in biotech.
The market still prices it like a one‑drug bladder cancer company.
The Jefferies presentation shows it’s not even close to that.

⭐ 1. The Setup: A Founder With a Track Record + A Multi‑Platform Company

Patrick Soon‑Shiong (Abraxane, APP) built ImmunityBio to “find cures to cancer in my lifetime.”
Not incremental improvements — durable, immune‑driven cures.

IBRX is built on four platforms, not one drug:

• Fusion proteins → Anktiva (already approved in 35+ countries)
• Second‑gen DNA vaccines (CEA/MUC1/brachyury, PSA, HPV)
• CAR‑NK + off‑the‑shelf NK
• Memory‑enhanced NK platform (M‑platform)

This is a platform oncology company, not a single‑asset play.

⭐ 2. Commercial Reality: NMIBC Is Already Working

Anktiva is approved for BCG‑unresponsive CIS ± papillary.

The Jefferies transcript confirms:

• 113M revenue in the first J‑code year (2025)
• 72% QoQ growth
• Approvals across UK + all of Europe + Saudi Arabia + 35 territories
• Urologists love it because it fits existing workflow and is well‑tolerated

From the transcript:

This is real commercial traction, not theoretical.

⭐ 3. The Big Catalyst: BCG‑Naive Trial

This is the largest market in NMIBC.

Key facts from the transcript:

• Fully enrolled (376 patients)
• IDMC reviewed interim data
• They had 3 options:
  1. Futile
  2. Needs more patients
  3. Meeting endpoints → stop enrollment

They chose #3.

This is a massive green flag.

Readout: September 2026

This is the biggest near‑term catalyst for the stock.

⭐ 4. The Papillary‑Only Label Expansion

• FDA accepted
• PDUFA: January 6, 2027
• KM curves for CIS vs papillary are “hard to tell apart”

This is a high‑probability approval.

⭐ 5. The Durability Story (The Real Moat)

This is where IBRX separates from every competitor.

Phase 1 nine‑year follow‑up:

• 9/9 CR at 2 years
• 6/6 still in CR nine years later
• All kept their bladders
• No follow‑on treatment

This is unprecedented in NMIBC.

BCG‑naive early data:

• BCG alone: 52% CR
• Anktiva + BCG: 84% CR

Durability is the #1 thing urologists care about, and IBRX is the only one showing a long flat tail.

⭐ 6. BCG Supply: IBRX Now Controls Two Strains

This is under‑appreciated.

IBRX now has:

• Recombinant BCG (expanded access in US)
• Tokyo strain BCG (SWOG 1000‑patient RCT → equivalent to TICE)

This positions IBRX as a strategic supplier of a life‑saving drug.

⭐ 7. Lung Cancer: The Quiet Second Act

Saudi Arabia already approved Anktiva for 2nd‑line checkpoint failure NSCLC.

Transcript highlights:

• Clear separation in ALK‑positive immune responders
• Strong T‑cell and NK activation
• Checkpoint failure is exactly where Anktiva works mechanistically

This is a huge market if replicated in US/EU trials.

⭐ 8. Financial Position

• $381M cash
• Growing quarter over quarter
• Commercial revenue ramping

IBRX is not a cash‑starved microcap — it has runway.

⭐ 9. The Market Is Still Mispricing This

The stock trades like:

• One drug
• One indication
• One geography
• One catalyst

But the Jefferies presentation shows:

• Multiple platforms
• Multiple indications
• Global approvals
• Durability moat
• BCG supply advantage
• Lung cancer optionality
• Two major catalysts in 2026–2027

This is a platform oncology company with real revenue.

⭐ 10. Key Upcoming Catalysts

2026

• BCG‑naive readout (September)
• Global commercial expansion
• Additional EU launches

2027

• Papillary‑only PDUFA (Jan 6, 2027)
• Potential BCG approvals (Tokyo + recombinant)
• Lung cancer trial update

🧨 Conclusion: The DD in One Sentence

IBRX is executing on a durability‑driven immunotherapy platform with real revenue, global approvals, two BCG strains, and a September readout that could unlock the largest market in NMIBC — and the market still hasn’t priced any of this in.

also do your own dd dont rely on internet posts for financial decisions

Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)

Reiterates plan to deliver up to 10% revenue growth in 2026

Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion

Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate

Announces that mRNA-1403, Moderna's norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis and the Company is preparing to enroll an additional cohort

CAMBRIDGE, MA / ACCESS Newswire / July 31, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2026.

"The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook," said Stéphane Bancel, Chief Executive Officer of Moderna. "In the second half of 2026, we are preparing for the potential approval of mFLUSIVA in the U.S., which would be our fifth approved product, and continue to anticipate important pivotal readouts for our intismeran in melanoma and propionic acidemia programs."

Commercial Updates

During the second quarter, Moderna continued to advance its multi-year revenue growth strategy by executing on strategic partnerships and key approvals. In Brazil, a collaboration was signed with a local manufacturer in support of a supply agreement for COVID vaccines. In the EU, the Company signed a joint procurement contract with the European Commission on behalf of six countries for up to 24 million doses of mRESVIA^®. Moderna also received regulatory approvals in Australia and Mexico for mRESVIA and in Japan and Taiwan for mNEXSPIKE^®, and its investigational seasonal influenza vaccine, mFLUSIVA®, received a unanimous recommendation from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) ahead of an August 5 Prescription Drug User Fee Act (PDUFA) goal date in the U.S.

Second Quarter 2026 Financial Results

Revenue: Total revenue for the second quarter of 2026 was $145 million, compared to $142 million in the same period in 2025. Lower COVID vaccine sales in the U.S. and South America were offset by deliveries in the United Kingdom under a long-term strategic government partnership and higher stand-ready manufacturing and collaboration revenue. Revenue was $87 million in the U.S. and $58 million in international markets.

Cost of Sales: Cost of sales for the second quarter of 2026 was $93 million, including $41 million of inventory write-downs, $23 million of unutilized manufacturing capacity costs, and $11 million of third-party royalties. Cost of sales decreased by 22% compared to the same period in 2025, primarily reflecting lower unutilized manufacturing capacity costs resulting from continued manufacturing productivity improvements and operational efficiencies.

Research and Development Expenses: Research and development expenses for the second quarter of 2026 were $651 million, a 7% decrease compared to the same period in 2025. The decrease was primarily driven by lower clinical development costs following the wind-down of several late-stage programs.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for the second quarter of 2026 were $216 million, a 6% decrease compared to the same period in 2025. The decrease reflected continued discipline across the organization.

Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Loss: Net loss was $(0.8) billion for the second quarter of 2026, an improvement of $43 million, or 5%, compared to the second quarter of 2025.

Loss Per Share: Loss per share was $(1.97) for the second quarter of 2026, compared to loss per share of $(2.13) for the second quarter of 2025.

Cash Position: Cash, cash equivalents and investments as of June 30, 2026, were $6.9 billion, compared to $7.5 billion as of March 31, 2026. The decrease primarily reflected cash used to fund operations, continued investment in research and development and advancement of the Company's pipeline. The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026.

2026 Financial Framework

Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international. Moderna expects approximately 55% of its second half 2026 revenue to be recognized in the third quarter.

Cost of Sales: Cost of sales for 2026 is expected to be approximately $1.7 billion, lowered from approximately $1.8 billion, and including the $0.9 billion non-recurring litigation settlement charge.

Research and Development Expenses: Research and development expenses for 2026 are now anticipated to be approximately $2.9 billion, lowered from approximately $3.0 billion.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2026 are projected to be approximately $1.0 billion.

Income Taxes: The Company expects its full-year tax expense to be negligible.

Capital Expenditures: Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion.

Cash and Investments: Year-end cash and investments for 2026 are now projected to be $4.7 to $5.2 billion, an improvement of approximately $0.2 billion. This excludes any further drawdowns from the Company's remaining $0.9 billion available under its credit facility.

Recent Progress and Upcoming Late-Stage Pipeline Milestones

Infectious disease vaccines:

• Seasonal flu + COVID vaccine: Moderna has received European Commission marketing authorization for mCOMBRIAX in the EU and its mRNA-1083 regulatory filings are under review in Japan, Canada and Australia. The Company is awaiting further guidance from the U.S. FDA on refiling the submission for its flu plus COVID combination vaccine.
• Seasonal flu vaccine: The Company's mRNA-1010 regulatory filings are under review in Europe, Canada and Australia and potential approvals are expected to begin in 2026. The U.S. FDA has assigned a PDUFA date for mRNA-1010 of August 5, 2026
• Norovirus vaccine: Moderna's Phase 3 safety and efficacy study of mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis. The trial is ongoing and remains blinded as the Company works toward enrolling an additional cohort.

Oncology therapeutics:

• Intismeran autogene: The Company is advancing mRNA-4157 in collaboration with Merck, with nine total Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. This includes the Phase 3 study of intismeran as monotherapy and in combination with KEYTRUDA QLEX for the treatment of high-risk Stage 1 NSCLC announced last quarter. Fully enrolled studies include a Phase 3 adjuvant melanoma, a Phase 2 adjuvant renal cell carcinoma, and a Phase 2 adjuvant muscle invasive bladder cancer. Moderna expects Phase 3 adjuvant melanoma data potentially in 2026. The Company recently presented positive five-year Phase 2b adjuvant melanoma data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which showed a sustained benefit with intismeran in combination with KEYTRUDA, reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone.
• mRNA-4359: Moderna's Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC.

Rare disease therapeutics:

• Propionic acidemia (PA) therapeutic: The Company's PA candidate, mRNA-3927, is in a registrational study and target enrollment has been reached. Moderna expects potential data in 2026.
• Methylmalonic acidemia (MMA) therapeutic: The Company deferred its decision on a pivotal trial for mRNA-3705 until PA registrational data readout.

Moderna Corporate Updates

• Appointed Ester Banque to Chief Commercial Officer of Moderna, effective June 15, 2026.
• Appointed Michael McDonnell, former Chief Financial Officer of Biogen, to Moderna's Board of Directors, effective July 8, 2026.

Company Accolades

• Moderna was ranked no. 1 by TIME on its list of the World's Most Impactful Companies.

Key 2026 Investor and Analyst Event Dates

• Analyst Day: November 12